| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/09/2006 | EP1688135A1 Sclerosing solution |
| 08/09/2006 | EP1688049A1 Dietary foodstuff |
| 08/09/2006 | EP1687642A2 Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors |
| 08/09/2006 | EP1687641A2 Treating neuropathic pain with neuropeptide ff receptor 2 agonists |
| 08/09/2006 | EP1687452A2 Human hinge core mimetibodies, compositions, methods and uses |
| 08/09/2006 | EP1687449A2 Antisense modulation of kinesin-like 1 expression |
| 08/09/2006 | EP1687430A1 Immunization against chlamydia infection |
| 08/09/2006 | EP1687427A2 Methods for modulating neuronal responses |
| 08/09/2006 | EP1687410A1 Antisense oligonucleotides optimized for kidney targeting |
| 08/09/2006 | EP1687349A2 Polyamine polymers |
| 08/09/2006 | EP1687337A1 A method for the treatment of malignant diseases by inhibiting nucleolin |
| 08/09/2006 | EP1687326A2 Method for obtaining natural products from plant material |
| 08/09/2006 | EP1687321A1 Nucleoside compounds for treating viral infections |
| 08/09/2006 | EP1687320A1 Novel analgesic compounds, extracts containing same and methods of preparation |
| 08/09/2006 | EP1687319A1 Phosphinic acid derivatives |
| 08/09/2006 | EP1687314A1 PREPARATION OF 1-AZA-2-OXA-DIBENZO [e,h] AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| 08/09/2006 | EP1687313A1 Indolyl-thien 3,4-b]pyrazin-3-one derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| 08/09/2006 | EP1687312A1 Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof |
| 08/09/2006 | EP1687311A1 Novel compounds |
| 08/09/2006 | EP1687310A1 Method for the catalytic production of hydrocodone and hydromorphone |
| 08/09/2006 | EP1687309A1 Pyrrolopyrimidine compounds useful in treatment of cancer |
| 08/09/2006 | EP1687308A2 Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride |
| 08/09/2006 | EP1687307A2 Substituted imidazo ring systems and methods |
| 08/09/2006 | EP1687306A1 Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| 08/09/2006 | EP1687305A1 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| 08/09/2006 | EP1687304A1 Substituted quinolines for the treatment of cancer |
| 08/09/2006 | EP1687303A1 4-substituted imidazoles |
| 08/09/2006 | EP1687302A1 5-substituted imidazoles |
| 08/09/2006 | EP1687301A1 Thiaepothilone for treating cancerous diseases |
| 08/09/2006 | EP1687299A1 Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treamtment and/or prevention of disorders modulated by a ppar |
| 08/09/2006 | EP1687298A1 Cycloalkyl derivatives of 3-hydroxy-4-pyridinones |
| 08/09/2006 | EP1687297A1 Triazine dimers for the treatment of autoimmune diseases |
| 08/09/2006 | EP1687296A1 Antibacterial aminoquinazolidinedione derivatives |
| 08/09/2006 | EP1687295A2 Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
| 08/09/2006 | EP1687294A2 Novel piperidine-substituted indoles-or hetero-derivatives thereof and their use as modulators of chemokine receptor (ccr-3) |
| 08/09/2006 | EP1687293A1 Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| 08/09/2006 | EP1687292A2 Vitamin d receptor modulators |
| 08/09/2006 | EP1687289A1 Vitamin d receptor modulators |
| 08/09/2006 | EP1687288A1 Substituted aryl cycloalkanol derivatives and methods of their use |
| 08/09/2006 | EP1687286A1 Developments in biologically active methylene blue derivatives (2) |
| 08/09/2006 | EP1687285A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors |
| 08/09/2006 | EP1687281A1 Synthesis of 2-chloro-3,6-dialkyl pyrazines |
| 08/09/2006 | EP1687279A1 7- [4-(4-chlorobenzyloxy) benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1h-3-benzazepinium maleate or tosylate as antipsychotics |
| 08/09/2006 | EP1687277A1 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| 08/09/2006 | EP1687275A1 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
| 08/09/2006 | EP1687274A1 Androgen receptor modulators |
| 08/09/2006 | EP1687268A1 Benzylether amine compounds useful as ccr-5 antagonists |
| 08/09/2006 | EP1687265A2 Vitamin d receptor modulators |
| 08/09/2006 | EP1687262A1 Bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators |
| 08/09/2006 | EP1687260A1 Nitroso derivatives of diphenylamine |
| 08/09/2006 | EP1687259A1 Cyclopentyl derivates |
| 08/09/2006 | EP1687258A2 Vitamin d receptor modulators |
| 08/09/2006 | EP1687257A2 AMINO-SUBSTITUTED ETHYLAMINO &Bgr;2 ADRENERGIC RECEPTOR AGONISTS |
| 08/09/2006 | EP1687255A2 Calixarenes as inhibitors of protein kinase b |
| 08/09/2006 | EP1687030A2 Combination of a dpp iv inhibitor and an anti-obesity or appetite regulating agent |
| 08/09/2006 | EP1687024A2 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
| 08/09/2006 | EP1687021A1 Method of removing transition metals, especially from metathesis reaction products |
| 08/09/2006 | EP1687015A2 Compositions for the treatment of diseases of the oral cavity and upper respiratory tract |
| 08/09/2006 | EP1687009A1 Anti-adhesion agent with gas bubble |
| 08/09/2006 | EP1687008A2 Food composition comprising glucosamine |
| 08/09/2006 | EP1687007A2 Solid and crystalline ibandronic acid |
| 08/09/2006 | EP1687006A1 Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients |
| 08/09/2006 | EP1687005A1 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents |
| 08/09/2006 | EP1687004A2 Pyridine compounds |
| 08/09/2006 | EP1687003A1 (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol for treating anxiety |
| 08/09/2006 | EP1687002A1 Fused heterocyclic compounds |
| 08/09/2006 | EP1687001A2 Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
| 08/09/2006 | EP1687000A2 Use of cyclooxygenase-2 inhibitors for the treatment of depressive disorders |
| 08/09/2006 | EP1686999A1 Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| 08/09/2006 | EP1686998A1 Phosphodiesterase 9 inhibition as treatment for obesity-related conditions |
| 08/09/2006 | EP1686997A1 Inhibitors of the mutant form of kit |
| 08/09/2006 | EP1686996A1 Quinazolinone compounds with reduced bioaccumulation |
| 08/09/2006 | EP1686995A1 Use of cathepsin k inhibitors for treating of severe bone loss diseases |
| 08/09/2006 | EP1686994A2 Use of dipeptidyl peptidase iv inhibitors |
| 08/09/2006 | EP1686993A2 Virucidal activities of cetylpyridinium chloride |
| 08/09/2006 | EP1686992A2 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| 08/09/2006 | EP1686991A1 Use of piketprofen for the preparation of a pharmaceutical composition to treat rosacea |
| 08/09/2006 | EP1686990A2 2-guanidinylimidazolidinedione compounds and methods of making and using thereof |
| 08/09/2006 | EP1686989A1 Use of 1,2-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 08/09/2006 | EP1686988A1 Indirubin-type compounds, compositions, and methods for their use |
| 08/09/2006 | EP1686987A2 Advanced indolinone based protein kinase inhibitors |
| 08/09/2006 | EP1686986A1 Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
| 08/09/2006 | EP1686985A2 Use of neurokinin antagonists in the treatment of urinary incontinence |
| 08/09/2006 | EP1686984A1 Use of c-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders |
| 08/09/2006 | EP1686983A1 Use of pentadienoic acid derivates for treatement of hyperuricemia |
| 08/09/2006 | EP1686982A2 Methods and compositions for the treatment of helicobacter pylori -associated diseases using endoperoxide bridge-containing compounds |
| 08/09/2006 | EP1686981A1 Combinational radiotherapy and chemotherapy compositions and methods |
| 08/09/2006 | EP1686980A1 Ppar agonists for the treatment of hcv infection |
| 08/09/2006 | EP1686979A2 Activation of hypoxia-inducible gene expression |
| 08/09/2006 | EP1686978A1 Use of idrocilamide for the preparation of a pharmaceutical composition of rosacea |
| 08/09/2006 | EP1686977A1 Use of a bigaunide derivative for protecting skin against uvb radiation |
| 08/09/2006 | EP1686976A2 Combination of proton pump inhibitor and sleep aid |
| 08/09/2006 | EP1686975A1 Use of fepradinol for the production of a pharmaceutical composition for the treatment of rosacea |
| 08/09/2006 | EP1686974A1 Extended release dosage forms of bupropion hydrochloride |
| 08/09/2006 | EP1686973A1 Compositions and methods for treatment of cardiovascular disorders and diseases |
| 08/09/2006 | EP1686972A1 Sprayable composition for the administration of vitamin d derivatives |
| 08/09/2006 | EP1686971A2 Use of haloarylpyrazole compounds in the control of parasite infestation on animals |
| 08/09/2006 | EP1686970A2 Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease |
| 08/09/2006 | EP1686969A1 Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aqueous vehicle |
| 08/09/2006 | EP1686965A2 Solid pharmaceutical preparation form |